| PRO-PAC Packaging Limited (PPG) ORDINARY FULLY PAID |
Materials |
$3 |
Becoming a substantial holder
|
3 Apr 2025 8:57AM |
$0.023 |
$0.018 |
fallen by
21.74%
|
|
| Big River Industries Limited (BRI) ORDINARY FULLY PAID |
Materials |
$121 |
Application for quotation of securities - BRI
|
3 Apr 2025 8:57AM |
$1.275 |
$1.395 |
risen by
9.41%
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$489 |
RC220 Phase 1 Trial Opens for Patient Enrolment
|
3 Apr 2025 8:57AM |
$1.145 |
$2.710 |
risen by
136.68%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- RC220 Phase 1 trial opens at Southside Cancer Care Centre.
- Trial aims to assess safety and pharmacokinetics of RC220 with doxorubicin.
- Initial enrollment of up to 33 patients with further assessments planned.
- Trial will provide data on cardioprotective properties and anticancer efficacy.
- Conducted across multiple sites in Australia, Hong Kong, and South Korea.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$316 |
Application for quotation of securities - BGD
|
3 Apr 2025 8:57AM |
$0.400 |
$1.325 |
risen by
231.25%
|
|
| Aspire Mining Limited (AKM) ORDINARY FULLY PAID |
Materials |
$132 |
Aspire Enters MoU on Trailer Design, Supply and Maintenance
|
3 Apr 2025 8:56AM |
$0.290 |
$0.260 |
fallen by
10.34%
|
|
| Navigator Global Investments Limited (NGI) FPO-U.S. INVESTOR PROHIBITED EXCEPT QPS |
Financials |
$1,454 |
Goldman Sachs Emerging Leaders Conference Presentation
|
3 Apr 2025 8:56AM |
$1.870 |
$2.960 |
risen by
58.29%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$13,795 |
Statement of CDIs on issue - NEM
|
3 Apr 2025 8:56AM |
$76.310 |
$148.500 |
risen by
94.60%
|
|
| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$38 |
Strategic law enforcement research program
|
3 Apr 2025 8:55AM |
$0.034 |
$0.050 |
risen by
47.06%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic research program established with ALERRT Centre at Texas State University.
- Focus on enhancing active shooter response training using XR technology.
- Initial two-year collaboration with potential for renewal based on mutual agreement.
- Research will optimize Operator XR's technology platform in high-stress law enforcement scenarios.
- ALERRT has trained over 300,000 first responders in the US.
- The collaboration aims to improve human performance in high-stress situations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,450 |
Change of Director's Interest Notice - RL
|
3 Apr 2025 8:54AM |
$2.860 |
$3.870 |
risen by
35.31%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,450 |
Change of Director's Interest Notice - ML
|
3 Apr 2025 8:54AM |
$2.860 |
$3.870 |
risen by
35.31%
|
|
| Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$386 |
Update - Notification of buy-back - RMC
|
3 Apr 2025 8:51AM |
$0.855 |
$0.975 |
risen by
14.04%
|
|
| Summerset Group Holdings Limited (SNZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$2,438 |
Ongoing Disclosure Notices
|
3 Apr 2025 8:51AM |
$10.190 |
$10.060 |
fallen by
1.28%
|
|
| EROAD Limited (ERD) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$197 |
Ongoing Disclosure Notice - John Scott
|
3 Apr 2025 8:51AM |
$0.850 |
$1.050 |
risen by
23.53%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$96 |
1st dose level cleared IV combination arm onCARlytics trial
|
3 Apr 2025 8:51AM |
$0.030 |
$0.305 |
risen by
916.67%
|
|
| Argent Biopharma Limited (RGT) ORDINARY FULLY PAID |
Health Care |
$5 |
CannEpil Receives Approval for Prescription in Germany
|
3 Apr 2025 8:49AM |
$0.130 |
$0.061 |
fallen by
53.08%
|
|
RGT - Price-sensitive ASX Announcement
Full Release
Key Points
- CannEpilâ„¢ has been approved for prescription in Germany.
- This approval expands Argent BioPharma's presence in the European market.
- Physicians can now prescribe CannEpilâ„¢, allowing eligible patients access.
- Approximately 816,000 people in Germany are diagnosed with epilepsy.
- CannEpilâ„¢ offers a vital alternative for patients with limited treatment options.
- The approval represents a significant step in the company's European expansion strategy.
- Argent BioPharma aims to provide innovative treatments for CNS disorders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$1,080 |
Acquisition of Flanco Group - Presentation
|
3 Apr 2025 8:48AM |
$2.550 |
$4.150 |
risen by
62.75%
|
|
TEA - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquisition estimated at approximately A$27 million.
- Flanco Group specializes in civil services and maintenance solutions.
- Transaction expected to enhance Tasmea's operational footprint in the Goldfields region.
- Deal projected to be earnings accretive, enhancing shareholder value.
- Expected completion of the transaction by early May 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$1,080 |
Acquisition of Flanco Group - Announcement
|
3 Apr 2025 8:47AM |
$2.550 |
$4.150 |
risen by
62.75%
|
|
TEA - Price-sensitive ASX Announcement
Full Release
Key Points
- Tasmea to acquire Flanco Pty Ltd and Flanco Kalgoorlie Pty Ltd.
- Completion of the acquisition expected in early May 2025.
- Flanco Group specializes in civil services and maintenance solutions.
- Flanco Group has achieved strong revenue growth with a CAGR of approximately 23%.
- The acquisition enhances Tasmea's operational capabilities.
- Total consideration of around A$50 million.
- Deal includes upfront cash payment and potential earn-out based on performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evolution Mining Limited (EVN) ORDINARY FULLY PAID |
Materials |
$25,626 |
Mungari Expansion Project Commences Commissioning
|
3 Apr 2025 8:46AM |
$7.110 |
$12.620 |
risen by
77.50%
|
|
| Perpetual Credit Income Trust (PCI) ORDINARY UNITS FULLY PAID |
Financials |
$811 |
Update - Dividend/Distribution - PCI
|
3 Apr 2025 8:43AM |
$1.180 |
$1.110 |
fallen by
5.93%
|
|
| Tower Limited (TWR) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Financials |
$598 |
Disclosure of ceasing to have substantial holding
|
3 Apr 2025 8:43AM |
$1.265 |
$1.745 |
risen by
37.94%
|
|
| Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$9 |
Change of Director's Interest Notice - Dr Ben Gil Price
|
3 Apr 2025 8:41AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$342 |
Update - Notification of buy-back - CVW
|
3 Apr 2025 8:40AM |
$0.460 |
$0.545 |
risen by
18.48%
|
|
| Treasury Wine Estates Limited (TWE) ORDINARY FULLY PAID |
Consumer Staple |
$3,948 |
Minimal impact expected from US tariffs on Aus and NZ wine
|
3 Apr 2025 8:38AM |
$9.100 |
$4.890 |
fallen by
46.26%
|
|
| Artemis Resources Limited (ARV) ORDINARY FULLY PAID |
Materials |
$30 |
GRE: Greentech and Artemis Consolidate Lithium Rights
|
3 Apr 2025 8:37AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
ARV - Price-sensitive ASX Announcement
Full Release
Key Points
- GreenTech and Artemis have consolidated lithium mineral rights.
- The joint venture is named Andover Lithium Pty Ltd.
- Each company owns 50% of Andover Lithium.
- The exploration package spans over 420 km² in the West Pilbara region.
- The combined tenements include undrilled outcrops of lithium-bearing pegmatite.
- The consolidation aims to attract major funding partners.
- GreenTech focuses on copper and zinc, while Artemis focuses on gold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GreenTech Metals Limited (GRE) ORDINARY FULLY PAID |
Materials |
$8 |
Greentech and Artemis Consolidate Lithium Rights
|
3 Apr 2025 8:37AM |
$0.076 |
$0.070 |
fallen by
7.89%
|
|
GRE - Price-sensitive ASX Announcement
Full Release
Key Points
- GreenTech Metals Limited and Artemis Resources consolidate lithium mineral rights.
- Joint venture named Andover Lithium Pty Ltd created.
- Over 420 km² lithium exploration package established.
- Each company owns 50% of Andover Lithium.
- Strategic move to attract funding partners.
- Consolidation allows focus on core resource expansion activities.
- No substantial management time or costs expected from the agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.